Irish-based drugmaker Elan Corporation has said that it has closed the sale of its share of multiple sclerosis drug Tysabri to its joint venture partner Biogen Idec.
Under the terms of the agreement, first announced in February, Elan has received $3.25 billion in cash and will receive double digit tiered royalty payments, on all indications, for the
life of Tysabri.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team